In addition, it highlights the fact that most BC patients are defined as HER2-negative tumors following fluorescence in situ hybridization (FISH) amplification methods, though they display some HER2 expression by immunohistochemistry (IHC) and therefore might respond to anti-HER2 therapies in some combination therapies. Here, ERBB2 is linked to breast cancer.